Tumor-infiltrating lymphocyte (TIL) therapy is a form of immunotherapy that leverages a patient's immune system to combat cancer. In this webinar, ONS and Hematology/Oncology Pharmacist Association (HOPA) members with experience in TIL therapy program development review operational best practices for adopting a TIL therapy program. A moderated panel of experts review legal considerations, information security, nurse education, hospital administration, pharmacy considerations and therapeutics, stakeholder analysis, and provider leadership considerations.
Access the evaluation for this video.
Focused content to elevate your practice at the point of care, including toolkits, quick guides, discussion tools, checklists, and clinical updates.
View All Nursing/Clinical Practice Resources